默沙東(MRK)正就收購美國製藥商SpringWorks(SWTX)進行深入談判

金吾財訊

2025/02/11

金吾財訊 | 默沙東(MRK)周一表示，正就收購美國癌症和罕見疾病製藥商SpringWorks Therapeutics(SWTX)進行深入談判。據媒體當天早些時候援引三位消息人士稱，如果談判成功，可能會在未來幾周簽署協議。他們沒有透露正在討論的具體條款。總部位於康涅狄格州斯坦福的SpringWorks於2019年在紐約上市，是一家商業階段的生物技術公司，開發用於治療各種癌症的藥物，包括罕見腫瘤和子宮癌。美國醫療保健行業的交易活動在2024年有所放緩後，目前正顯示出回暖的跡象。強生公司上個月同意以約146億美元收購Intra-Cellular Therapeutics。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2510487281"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510487281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510487281?lang=zh_TW&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","is_english":false,"pubTime":"2025-02-11 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510487281","market":"other","top_or_hot":-1,"title":"默沙東(MRK)正就收購美國製藥商SpringWorks(SWTX)進行深入談判","media":"金吾財訊","content":"<html><body><p>金吾財訊 | <a href=\"https://laohu8.com/S/MRK\">默沙東</a>(MRK)周一表示，正就收購美國癌症和罕見疾病製藥商SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>(SWTX)進行深入談判。據媒體當天早些時候援引三位消息人士稱，如果談判成功，可能會在未來幾周簽署協議。他們沒有透露正在討論的具體條款。總部位於康涅狄格州斯坦福的SpringWorks於2019年在紐約上市，是一家商業階段的生物技術公司，開發用於治療各種癌症的藥物，包括罕見腫瘤和子宮癌。美國醫療保健行業的交易活動在2024年有所放緩後，目前正顯示出回暖的跡象。<a href=\"https://laohu8.com/S/JNJ\">強生</a>公司上個月同意以約146億美元收購Intra-Cellular Therapeutics。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙東(MRK)正就收購美國製藥商SpringWorks(SWTX)進行深入談判</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙東(MRK)正就收購美國製藥商SpringWorks(SWTX)進行深入談判\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">金吾財訊 </p>\n<p class=\"h-time smaller\">2025-02-11 16:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>金吾財訊 | <a href=\"https://laohu8.com/S/MRK\">默沙東</a>(MRK)周一表示，正就收購美國癌症和罕見疾病製藥商SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>(SWTX)進行深入談判。據媒體當天早些時候援引三位消息人士稱，如果談判成功，可能會在未來幾周簽署協議。他們沒有透露正在討論的具體條款。總部位於康涅狄格州斯坦福的SpringWorks於2019年在紐約上市，是一家商業階段的生物技術公司，開發用於治療各種癌症的藥物，包括罕見腫瘤和子宮癌。美國醫療保健行業的交易活動在2024年有所放緩後，目前正顯示出回暖的跡象。<a href=\"https://laohu8.com/S/JNJ\">強生</a>公司上個月同意以約146億美元收購Intra-Cellular Therapeutics。</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"歐康維視生物-B","start_time":0,"source_url":"285295","article_id":"2510487281","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510487281","pubTimestamp":1739262495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾財訊","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾財訊 | 默沙東(MRK)周一表示，正就收購美國癌症和罕見疾病製藥商SpringWorks Therapeutics(SWTX)進行深入談判。據媒體當天早些時候援引三位消息人士稱，如果談判成功，可能會在未來幾周簽署協議。他們沒有透露正在討論的具體條款。總部位於康涅狄格州斯坦福的SpringWorks於2019年在紐約上市，是一家商業階段的生物技術公司，開發用於治療各種癌症的藥物，包括罕見腫瘤和子宮癌。美國醫療保健行業的交易活動在2024年有所放緩後，目前正顯示出回暖的跡象。強生公司上個月同意以約146億美元收購Intra-Cellular Therapeutics。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01477":"欧康维视生物-B","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","BK1191":"制药","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","MRK":"默沙东","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","SWTX":"SpringWorks Therapeutics, Inc.","BK4585":"ETF&股票定投概念","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0058720904.USD":"联博国际健康护理基金A","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4559":"巴菲特持仓","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC"},"translate_title":"Merck (MRK) is in advanced talks to acquire US drugmaker SpringWorks (SWTX)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"SWTX":1,"MRK":1},"content_text":"金吾財訊 | 默沙東(MRK)周一表示，正就收購美國癌症和罕見疾病製藥商SpringWorks Therapeutics(SWTX)進行深入談判。據媒體當天早些時候援引三位消息人士稱，如果談判成功，可能會在未來幾周簽署協議。他們沒有透露正在討論的具體條款。總部位於康涅狄格州斯坦福的SpringWorks於2019年在紐約上市，是一家商業階段的生物技術公司，開發用於治療各種癌症的藥物，包括罕見腫瘤和子宮癌。美國醫療保健行業的交易活動在2024年有所放緩後，目前正顯示出回暖的跡象。強生公司上個月同意以約146億美元收購Intra-Cellular Therapeutics。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}